Accepted for Publication: June 7, 2022.
Published Online: October 6, 2022. doi:10.1001/jamaoncol.2022.3755
Corresponding Author: Fabio Conforti, MD, Division of Medical Oncology for Melanoma & Sarcoma, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy (email@example.com).
Author Contributions: Dr Conforti had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Authors Conforti, Pala, Viale, and Gelber contributed equally to the work.
Concept and design: Conforti, Pala, Bagnardi, De Pas, Colleoni, Buyse, Gianni, Winer, Loibl, Cortés, Viale.
Acquisition, analysis, or interpretation of data: Conforti, Bagnardi, Hortobagyi, Loibl, Piccart-Gebhart, Wolff, Gelber.
Drafting of the manuscript: Conforti, Pala, Bagnardi, De Pas, Colleoni, Buyse.
Critical revision of the manuscript for important intellectual content: Conforti, Pala, Bagnardi, De Pas, Hortobagyi, Gianni, Winer, Loibl, Cortés, Piccart-Gebhart, Wolff, Viale, Gelber.
Statistical analysis: Conforti, Bagnardi.
Administrative, technical, or material support: ConfortI, Gelber.
Supervision: Conforti, Pala, Bagnardi, Gianni, Loibl, Cortés, Piccart-Gebhart, Viale.
Conflict of Interest Disclosures: Dr Colleoni reported grants from Roche outside the submitted work. Dr Buyse reported nonfinancial support from IDDI, stockholder outside the submitted work. Dr Hortobagyi reported personal fees from Novartis outside the submitted work. Dr Gianni reported advisory board membership, consultancy fees, or support to institution from AstraZeneca, Celgene, Eli Lilly, Roche, Pfizer, Seattle Genetics, Artemida Pharma Ltd, Zymeworks; from METIS Precision Medecine, Novartis, Revolution Medicines, Synaffix, Menarini Ricerche, Amgen, Biomedical Insights, and Denali Therapeutics, outside the submitted work; in addition, Dr Gianni had a patent for European Patent Application n. 12195182.6 and 12196177.5; Roche; no compensation was provided. Dr Winer reported consultancy fees from Carrick Therapeutics; honoraria from Genentech/Roche; consultancy fees for advisory board membership, lectures or writing fees, or fees paid to institution from Genomic Helath, GSK, Jounce Therapeutics, and Leap Therapeutics outside the submitted work. Dr Loibl reported honoraria for advisory board membership, lecture and/or writing fees, and/or fees paid to institution from Abbvie, Amgen, AstraZeneca, BMS, Celgene, EirGenix, GSK, Gilead, Lilly, Merck, Novartis, Pfizer, Pierre Fabre, Seagen, DSI, Sanofi, Roche, outside the submitted work; in addition, Dr Loibl had a patent for EP14153692.0 pending Immunsignature in TNBC, paid to institute, a patent for EP21152186.9 pending Signature for CDK 4/6 Inhibitor, paid to institute, a patent for EP15702464.7 issued predicting response to an Anti–HER2-containing therapy, paid to institute, a patent for EP19808852.8 pending GeparNuevo, paid to institute, and a patent for Digital Ki67 Evaluator with royalties paid VM Scope GmbH, paid to institute. Dr Cortés reported personal fees, honoraria for advisory board membership, lecture and/or writing fees, travel expenses, reasearch funding, stock holdings, and/or fees paid to institution from Roche, Celgene, Cellestia Consulting, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp & Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer, Ellipses, Hibercell, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Novartis, Eisai, Pfizer, Samsung, Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta, Bayer Healthcare, Guardanth Health, Merck Sharp & Dohme, Piqur Therapeutics, Puma C, Queen Mary University of London, Medsir Nektar Therapeutics, Leuko, during the conduct of the study; personal fees, honoraria for advisory board membership, lecture and/or writing fees, travel expenses, reasearch funding, stock holdings, and/or fees paid to institution Roche, Celgene, Cellestia, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp & Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer, Ellipses, Hibercell, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Novartis, Eisai, Pfizer, Samsung Bioepis, Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta, Bayer Healthcare, Guardanth Health, Merck Sharp & Dohme, Piqur Therapeutics, Puma C, Queen Mary University of London, Medsir, Nektar Therapeutics, and Leuko, outside the submitted work; in addition, Dr Cortés had a patent for Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde issued WO 2014/199294 A and a patent for Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy. Aleix Prat, Antonio Llombart, Javier Cortés issued US 2019/0338368 A1. Dr Piccart-Gebhart reported personal fees, honoraria for advisory board membership, lecture and/or writing fees, travel expenses, reasearch funding, stock holdings, and/or fees paid to institution from AstraZeneca, Camel-IDS/Precirix, Frame Therapeutics, Gilead, Immunomedics, Immutep, Lilly, Menarini, MSD, NBE Therapeutics, Novartis, Odonate, Pfizer, Roche-Genentech, SeaGen, Seattle Genetics, Oncolytics, AstraZeneca, Immunomedics, Menarini, Radius, Servier, and Synthon outside the submitted work. Dr Viale reported personal, advisory board, and/or consultancy fees from Roche, AstraZeneca, MSD, Daichii Sankyo, Agilent, Ventana, and Pfizer outside the submitted work. Dr Gelber reported grants from Roche, AstraZeneca, Merck, and Novartis to institution outside the submitted work. No other disclosures were reported.
L , Pienkowski
T , Im
et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol
. 2012;13(1):25-32. doi:10.1016/S1470-2045(11)70336-9
M , Procter
M , Fumagalli
et al; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years’ Follow-Up. J Clin Oncol
. 2021;39(13):1448-1457. doi:10.1200/JCO.20.01204
HJ , Curigliano
G , Thürlimann
et al; Panelists of the St Gallen Consensus Conference. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol
. 2021;32(10):1216-1235. doi:10.1016/j.annonc.2021.06.023
F , Pala
L , Sala
et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ
. 2021;375:e066381. doi:10.1136/bmj-2021-066381
AM , Amaria
RN , Rozeman
et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med
. 2021;27(2):301-309. doi:10.1038/s41591-020-01188-3
LD , Hortobagyi
GN , Buzdar
AU , Ames
FC , Blumenschein
GR . Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res
. 1986;46(5):2578-2581.PubMedGoogle Scholar
HM , Hiller
L , Dunn
et al; ARTemis Investigators Group. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial. Ann Oncol
. 2017;28(8):1817-1824. doi:10.1093/annonc/mdx173
G , Loibl
S , Untch
et al; GBG/AGO-B study groups. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto). Ann Oncol
. 2014;25(12):2363-2372. doi:10.1093/annonc/mdu455
S , Schneeweiss
A , Huober
et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J Clin Oncol
. 2021;39:505-506. doi:10.1200/JCO.2021.39.15_suppl.506
MD , Chaft
JE , William
et al; University of Texas MD Anderson Lung Cancer Collaborative Group. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol
. 2014;15(1):e42-e50. doi:10.1016/S1470-2045(13)70334-6PubMedGoogle ScholarCrossref
SA , Martin
M , Jung
et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE Study. J Clin Oncol
. 2019;37(25):2206-2216. doi:10.1200/JCO.19.00882
WF , Yau
C , Chen
et al. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol
. 2021;7(11):1654-1663. doi:10.1001/jamaoncol.2021.3690
C , Osdoit
M , van der Noordaa
et al; I-SPY 2 Trial Consortium. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol
. 2022;23(1):149-160. doi:10.1016/S1470-2045(21)00589-1
S , Thompson
JR , Riley
RD , Abrams
KR . Bayesian meta-analytical methods to incorporate multiple surrogate endpoints in drug development process. Stat Med
. 2016;35(7):1063-1089. doi:10.1002/sim.6776
EG , Städler
N , Ciani
O , Taylor
RS , Bujkiewicz
S . Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer. Cancer Epidemiol
. 2020;64:101665. doi:10.1016/j.canep.2019.101665
S , Marschner
IC . Interim analysis of continuous long-term endpoints in clinical trials with longitudinal outcomes. Stat Med
. 2003;22(11):1787-1805. doi:10.1002/sim.1311
LG , Burzykowski
T , Legrand
et al. Using an interim analysis based exclusively on an early outcome in a randomized clinical trial with a long-term clinical endpoint. Pharm Stat
. 2021:1-11.PubMedGoogle Scholar
H , Gray
R , Braybrooke
et al; EBCTCG. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med
. 2017;377(19):1836-1846. doi:10.1056/NEJMoa1701830
J , Cohen
JD , Wang
et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol
. 2019;5(12):1710-1717. doi:10.1001/jamaoncol.2019.3616
N , Swift
C , Jenkins
et al. Primary results of the cTRAK TN trial: A clinical trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast cancer. Presented at: 2021 San Antonio Breast Cancer Symposium; virtual. Abstract GS3-06.